retatrutide type 2 diabetes phase 2 results 2024 2025 UK Guide: Key Facts on the New Weight-Loss Drug New Kind of Diabetes Drug

This can make a big difference

The OASIS 4 trial found that patients taking the oral Wegovy pill lost an average of 13.6% of their body weight over 64 weeks, while the STEP 1 trial for injectable Wegovy showed 14.9% weight loss over 68 weeks

Some GLP-1 receptor agonists have demonstrated cardiovascular benefits in specific populations

Early evidence suggests that individuals using GLP-1s spend significantly less money at the grocery store, shifting their purchasing habits away from snacks, alcohol, and carbohydrates while also increasing demand for high-protein and nutrient-dense foods (e.g., Roe, 2025

There are zero administrative fees or PMPM fees charged to employers

Perry, T